Survey of Victorian ophthalmologists who use ranibizumab to treat age‐related macular degeneration: to identify current practice and modifiable risk factors relevant to post‐injection endophthalmitis

Publisher： John Wiley & Sons Inc

E-ISSN： 1442-9071|43|3|277-279

ISSN： 1442-6404

Source： CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol.43, Iss.3, 2015-04, pp. : 277-279

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age‐related macular degeneration patients

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Implementation studies of ranibizumab for neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 92, Iss. 1, 2014-02 ,pp. : 98-98

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of Statins and Angiotensin Converting Enzyme Inhibitors (ACE-Is) and the Risk of Age-Related Macular Degeneration: Nested Case-Control Study

By  

Current Drug Safety, Vol. 3, Iss. 1, 2008-01 ,pp. : 24-26

Bentham Science Publishers

Access to resources Recommend Favorite

One‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 2, 2018-02 ,pp. : 197-204

John Wiley & Sons Inc

Access to resources Recommend Favorite

Younger Siblings, C-Reactive Protein, and Risk of Age-Related Macular Degeneration

By Cohn Amy C.   Busija Lucy   Robman Liubov D.   Dimitrov Peter N.   Varsamidis Mary   Lim Lyndell L.   Baird Paul N.   Guymer Robyn H.  

American Journal of Epidemiology, Vol. 177, Iss. 9, 2013-05 ,pp. : 933-943

Oxford University Press

Access to resources Recommend Favorite